ライフサイエンスコーパス: hypnotic

1 in reuptake inhibitors) and 27.4% a sedative/hypnotic.

2 respondents (14.9%) had ever used a sedative-hypnotic.

3 g; n = 575) immediately after injection of a hypnotic.

4 n and need for constant infusion of sedative-hypnotics.

5 easing the use of antipsychotics or sedative-hypnotics.

6 e sedation and serve as targets for sedative hypnotics.

7 the majority of clinically relevant sedative-hypnotics.

8 sychotics, antidepressants, anxiolytics, and hypnotics.

9 er flies, and is modulated by stimulants and hypnotics.

10 idely used anxiolytics, anticonvulsants, and hypnotics.

11 enatally exposed to benzodiazepines and/or z-hypnotics.

12 icidal" with each of the modern FDA-approved hypnotics.

13 ects of neurobiological response to sedative-hypnotics.

14 re anxiety that was unresponsive to sedative hypnotics.

15 and 8.8% after the crash), nonbenzodiazepine hypnotics (5.9% before the crash and 6.0% after the cras

16 of 16), antipsychotics (10 of 12), sedative-hypnotics (6 of 10), and stimulants (6 of 10).

17 ystem and to thereby determine their role in hypnotic action.

18 binding density, abuse liability, subjective hypnotic actions and seizure susceptibility, we assessed

19 ocus coeruleus, it may support analgesic and hypnotic actions attributed to inhibition of those neuro

20 omplex also failed to extend the sedative or hypnotic actions of aziPm and was indistinguishable from

21 ired for the sedative, and contribute to the hypnotic actions of this anesthetic.

22 termination of their potency and duration of hypnotic activity in mice after intravenous administrati

23 most commonly dispensed medications included hypnotics, ADHD medications, anxiolytics, and selective

24 35; 95% CI, 21.45-37.24; p < 0.001), and the hypnotic agent dose (51.3% vs 17.1% of maximum hypnotic

25 pnotic agent dose (51.3% vs 17.1% of maximum hypnotic agent dose given in the cohort; p < 0.001) were

26 Hypnotic agent dose was associated with coma (adjusted c

27 eived either etomidate or ketamine as a sole hypnotic agent were included; those with preintubation c

28 Etomidate is a nonbarbiturate sedative hypnotic agent with no analgesic properties.

29 Propofol is also a sedative hypnotic agent with rapid onset and short duration of ac

30 e intubation when used in conjunction with a hypnotic agent.

31 ave been implicated in responses to sedative/hypnotic agents (including neuroactive steroids), anxiet

32 ICDs under conscious sedation with combined hypnotic agents and deep sedation with etomidate is a sa

33 atory using conscious sedation with combined hypnotic agents and deep sedation with etomidate.

34 sensitive targets for several commonly used hypnotic agents and mediate tonic neuronal inhibition.

35 Among hypnotic agents that enhance GABAA receptor function, et

36 thesiology are employing new potent sedative hypnotic agents to accomplish effective pediatric sedati

37 ies have shown that a wide range of sedative/hypnotic agents, including ethanol, induce sleep when mi

38 s anticonvulsants, anxiolytics, and sedative-hypnotic agents.

39 increased risk of initiating treatment with hypnotics (AHR, 1.74 [95% CI, 1.33-2.29]) and anxiolytic

40 (aHR, 2.68; 95% CI, 1.54-4.64), sedatives or hypnotics (aHR, 2.70; 95% CI, 1.40-5.19), or nonsteroida

41 10 [95% CI, 18.30-29.20]) and treatment with hypnotics (AHR, 9.08 [95% CI, 5.52-14.90]).

42 used as anxiolytics, and for short-half-life hypnotics (all zopiclone).

43 was to estimate the risk of repeated use of hypnotics among individuals with celiac disease as a pro

44 s received painful thermal stimuli following hypnotic analgesia on their own hand, but also when they

45 two standardized scales, and then exposed to hypnotic analgesia training to control cold pressor pain

46 trical activity) of intact resting muscle by hypnotics, analgesia is required to prevent pain-evoked

47 ubunit containing GABAARs contributes to the hypnotic and amnestic actions of the intravenous anesthe

48 Anxiolytic/sedative/hypnotic and antidepressant medication use were independ

49 nes, which are often used for their sedative/hypnotic and anxiolytic effects.

50 e we report that ENT1-null mice show reduced hypnotic and ataxic responses to ethanol and greater con

51 We conclude that both hypnotic and non-hypnotic doses of benzodiazepines may b

52 inazolinone, Quaalude), an infamous sedative-hypnotic and recreational drug from the 1960s-1970s.

53 4.7%; difference, 2.6%; 95% CI, 1.6%-3.5%), hypnotic and sedative (11.0% vs 5.3%; difference, 5.7%;

54 medication class (antipsychotic, anxiolytic, hypnotic and sedative, antidepressant, and psychostimula

55 of person-crashes started nonbenzodiazepine hypnotics and 1.2% stopped nonbenzodiazepine hypnotics,

56 l agents, including anaesthetics, sedatives, hypnotics and antidepressants(1-3).

57 variety of behavioral responses to sedative-hypnotics and may directly facilitate progress in human

58 icularly addressing the fields of sedatives, hypnotics and neuromuscular blockers, however, there is

59 Regional anesthesia, as well as hypnotics and opioids, promotes intraoperative muscle re

60 Despite widespread use of standard hypnotics and sedating antidepressants for chronic insom

61 duals [9.9%] vs 1119 individuals [7.7%]) and hypnotics and sedatives (1609 individuals [12.2%] vs 151

62 f anxiolytics (OR, 1.34; 95% CI, 1.12-1.60), hypnotics and sedatives (OR, 1.21; 95% CI, 1.02-1.43), o

63 isk of ALS (eg, among individuals prescribed hypnotics and sedatives 0-1 year before diagnosis: odds

64 onset but were substantial for anxiolytics, hypnotics and sedatives, and antidepressants.

65 ontrol study, prescribed use of anxiolytics, hypnotics and sedatives, or antidepressants was associat

66 familial confounding, with the exception of hypnotics and sedatives.

67 and 1.40 [95% CI, 1.30-1.50] in children for hypnotics and sedatives; RR, 1.38 [95% CI, 1.29-1.47] in

68 For the induction dose of hypnotics and the initial dose of other drugs that have

69 Benzodiazepine hypnotics and the related nonbenzodiazepine hypnotics (z

70 of a structurally diverse group of sedative, hypnotic, and anesthetic drugs, including the volatile a

71 allosteric modulator and heavily prescribed hypnotic, and DMCM, a negative allosteric modulator with

72 and to test their contributions to sedative, hypnotic, and immobilizing anesthetic actions.

73 Daily doses of all opioid, sedative, hypnotic, and major tranquilizer drugs administered to e

74 ct as endogenous anxiolytic, anticonvulsant, hypnotic, and sedative agents, actions that are principa

75 dosages of antidepressants, antipsychotics, hypnotics, and antidementia medications were allowed.

76 re antidepressants, antipsychotics, sedative-hypnotics, and antidepressant-antipsychotic combinations

77 tonin reuptake inhibitors, nonbenzodiazepine hypnotics, and antihistamines for more than 4 weeks was

78 tions of antihypertensives, antidepressants, hypnotics, and anxiolytics.

79 hypnotics and 1.2% stopped nonbenzodiazepine hypnotics, and drivers in 8.4% of person-crashes started

80 cluding cannabinoids, psychedelics, sedative-hypnotics, and immunotherapeutics, such as vaccines.

81 ntidepressants, antipsychotics, anxiolytics, hypnotics, and mood-stabilizers, with statins as a negat

82 nzodiazepine benzodiazepine receptor agonist hypnotics, and opioids.

83 y alcohol, marijuana or cocaine, anesthetics/hypnotics, and oral opioids.

84 ications, including antipsychotics, sedative-hypnotics, and strong anticholinergic agents.

85 owever, the prescriptions of antipsychotics, hypnotics, and the negative control outcome, statins, sh

86 antidepressants, anxiolytics, sedatives, and hypnotics, and was consistent across age groups.

87 zepines; anxiolytics, nonbenzodiazepines, or hypnotics; and drugs not prescribed for home use.

88 n reached on the precise mechanisms by which hypnotic anesthetic agents produce their effects.

89 se of the BIS monitor results in less use of hypnotic anesthetic drugs, decreased time to extubation,

90 Chlormethiazole has sedative, hypnotic, anticonvulsant and neuroprotective properties.

91 n for relevant medications (antidepressants, hypnotics/anxiolytics, antipsychotics) during 12 months

92 Epidemiological studies show that hypnotics are associated with an increased risk for suic

93 COVID-19 pandemic onset was an increase in Z-hypnotic as well as SSRI and SNRI prescriptions in both

94 Further research testing or clinical use of hypnotics as OSA alternative treatments should be discou

95 Use of sedative-hypnotics before surgery is common, but its effect on po

96 This review focused on modern, FDA-approved hypnotics, beginning with the introduction of benzodiaze

97 This review focused on modern, FDA-approved hypnotics, beginning with the introduction of benzodiaze

98 the anxiolytic, anticonvulsant, and sedative-hypnotic benzodiazepines.

99 of using benzodiazepines, nonbenzodiazepine hypnotics, beta-blockers, selective serotonin reuptake i

100 de pERK staining showed elevated activity in hypnotic brain regions in glyt1-/- mutants under baselin

101 cern is that benzodiazepine receptor agonist hypnotics can cause parasomnias, which in rare cases may

102 also accumulating evidence of high levels of hypnotic capacity in all groups with dissociative sympto

103 observed in benzodiazepine receptor agonist hypnotic clinical trials.

104 e hypersensitive to melatonin, but not other hypnotic compounds.

105 Focused hypnotic concentration is a model for brain control over

106 , 1.87; 95% CI, 1.70-2.06), receive sedative hypnotics concurrently (40.7% vs 7.6%, adjusted RR, 5.46

107 by implicit suggestion and occur outside the hypnotic context.

108 rs identified could improve benzodiazepine/z-hypnotic deprescribing on adult mental health wards.

109 ng the neural underpinnings of self-reported hypnotic depth, offering a template for future investiga

110 rivation, and can be induced by conventional hypnotics, diazepam and sodium pentobarbital.

111 Hypnotics did not affect genioglossus responsiveness (hi

112 data indicating parallels between controlled hypnotic dissociative states and uncontrolled pathologic

113 lipopolysaccharide immediately followed by a hypnotic dose of etomidate, carboetomidate, or vehicle a

114 We conclude that both hypnotic and non-hypnotic doses of benzodiazepines may be associated with

115 ntral apnea, we administered nonhypnotic and hypnotic doses of diazepam to nine adult male Sprague-Da

116 bral cortical levels of 3alpha,5alpha-THP at hypnotic doses of ethanol.

117 Propofol is the most commonly used sedative-hypnotic drug for noxious procedures, yet the molecular

118 at dexmedetomidine could serve as a sedative-hypnotic drug to enhance clearance of harmful waste from

119 , these data suggest little or no benefit of hypnotic drug treatment on neurogenesis parameters in yo

120 Previous studies of sleep and hypnotic drug use in space have been limited to post-fli

121 hy, and subjective sleep characteristics and hypnotic drug use via daily logs, in-flight and during E

122 Additionally, after stratifying for hypnotic drug use, our results indicated that some disea

123 Stratifying for the hypnotic drug use, our sensitivity analyses indicated th

124 ors and diseases, in groups with and without hypnotic drug use.

125 seases, while also considering the impact of hypnotic drug use.

126 , our sensitivity analyses indicated that in hypnotic drug users, education (P = 0.034) and physical

127 Antianxiety or hypnotic drug visits, previously the largest category, d

128 sedative, and analgesic effects of the novel hypnotic drug, gaboxadol.

129 le incidence of overdoses involving sedative/hypnotic drugs and psychotropic medications decreased in

130 ut it should be applicable to other sedative/hypnotic drugs and to testing cerebellar mutant mice or

131 ugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [s

132 Approved hypnotic drugs have clearly been shown to improve subjec

133 ication and quantification of three sedative-hypnotic drugs namely diazepam, chlordiazepoxide and ket

134 ession, self-reported general health, use of hypnotic drugs or other medications, time spent in bed a

135 owever, we show that the ability of sedative/hypnotic drugs to enhance tonic inhibition in the mouse

136 ers when considering the ability of sedative/hypnotic drugs to enhance tonic inhibition.

137 The use of antianxiety/hypnotic drugs was significantly higher for women in car

138 , actigraphy, and the dosage of sedative and hypnotic drugs were recorded at baseline, therapy termin

139 Whether the administration of hypnotic drugs, by promoting sleep, especially in older

140 ated with abnormal sleep duration upon using hypnotic drugs.

141 neurosteroids, antiepileptics, and sedative/hypnotic drugs.

142 omnia, they suggest that coprescription of a hypnotic during initiation of an antidepressant may be b

143 or patients in need of benzodiazepines and z-hypnotics during pregnancy; however, these findings need

144 ta, USA) and novel 'soft-drug' sedatives and hypnotics (e.g. CNS-7259X and TD-4756) as well as a nove

145 MP system of the LC in the modulation of the hypnotic effect of alpha-2 adrenergic agonists remains u

146 ponent of the neuronal pathway mediating the hypnotic effect of ethanol and its antagonism by Ro15-45

147 5alpha-THP levels in cerebral cortex and the hypnotic effect of ethanol.

148 possibility is that anesthetics exert their hypnotic effects by hijacking endogenous arousal circuit

149 old increase in the duration of sedative and hypnotic effects compared with control mice without UV i

150 ral cortical levels of 3alpha,5alpha-THP and hypnotic effects in male rats.

151 effects of low dose ethanol and the sedative-hypnotic effects of a high dose, while reduced astrocyte

152 Behaviorally, the anxiolytic and sedative/hypnotic effects of alcohol are markedly reduced, and co

153 o-cortical pathways seem to be linked to the hypnotic effects of anesthesia and deep sedation.

154 The hypnotic effects of ethanol are also substantially dimin

155 However, the mechanisms of hypnotic effects of ethanol remain unclear.

156 indicate that A2AR is a key receptor for the hypnotic effects of ethanol, and pretreatment of caffein

157 mice are also less sensitive to the sedative/hypnotic effects of ethanol, as shown by more rapid reco

158 o altered the acute stimulatory and sedative-hypnotic effects of ethanol.

159 ral intoxication, as assayed by the sedative/hypnotic effects of ethanol.

160 caffeine might be a strategy to counter the hypnotic effects of ethanol.

161 al development and tolerance to the sedative-hypnotic effects of GABA(A)R positive modulators.

162 contributors to sedative, immobilizing, and hypnotic effects of intravenous anesthetics, a role for

163 utyric acid-A receptor is likely to have the hypnotic effects of propofol without the cardiac depress

164 ecessarily the only) anatomic site mediating hypnotic effects of these compounds.

165 hanol and are more sensitive to the sedative/hypnotic effects of this drug than controls.

166 channels, and thereby achieve their sedative-hypnotic effects.

167 ay a role in their immobilizing and sedative-hypnotic effects.

168 tion with both doses of ethanol, blocked its hypnotic effects.

169 cium signaling diminished sensitivity to the hypnotic effects.

170 evelop rapid tolerance to ethanol's sedative/hypnotic effects.

171 han other relaxation strategies that include hypnotic elements.

172 ssification models that predicted self-rated hypnotic experience based on the extracted feature sets.

173 l Attention Networks (DAN) contribute to the hypnotic experience.

174 the safety of prenatal benzodiazepine and z-hypnotic exposure and its association with long-term neu

175 the effect of prenatal benzodiazepine and z-hypnotic exposure and long-term neurodevelopment in chil

176 f the probability of benzodiazepine and/or z-hypnotic exposure as a function of potential confounders

177 y effects, and, consequently, may be a safer hypnotic for older patients.

178 observational studies suggested that use of hypnotics for insomnia was associated with increased ris

179 its, including diverse responses to sedative-hypnotics, have been detected on distal chromosome 1 in

180 za; [3] medication: anxiolytic, sedative, or hypnotic in an adult older than 65 years; benzodiazepine

181 icity from accentuated responses to sedative hypnotics in active cocaine-abusing subjects.

182 ation of treatment with benzodiazepines or z-hypnotics in early, mid, or late pregnancy on the childr

183 ing evidence-based guidelines for the use of hypnotics in the management of chronic insomnia.

184 the evidence for and against the claim that hypnotics increase the risk of suicide.

185 e (Lunesta(R)), a nonbenzodiazepine sedative hypnotic, increased N2 spindle density (number/minute) b

186 n with opioids, preoperative use of sedative-hypnotics increases the risk of adverse outcomes after c

187 The hypnotic inductions consisted of cooling imagery and sug

188 s anxiolytics, anticonvulsants, and sedative/hypnotics is limited by rapid metabolism.

189 Hypnotic maintenance was performed with sevoflurane 3% o

190 receive a prescription for antidepressant or hypnotic medication and to attend their GP both before a

191 s do not support the routine prescription of hypnotic medication for mitigating suicidal ideation in

192 ity result from CNS impairments from a given hypnotic medication or whether such medication decreases

193 c variables, comorbidities, and nonmelatonin hypnotic medication use.

194 to received antidepressants and antianxiety/hypnotic medications (five and three times more likely,

195 Hypnotic medications are also efficacious but must be ca

196 The review findings indicate that hypnotic medications are associated with suicidal ideati

197 to achieve tight glycemic control, sedative-hypnotic medications for insomnia or anxiety, and prosta

198 o, 1.85; 95% CI, 1.06-3.24) but not sedative-hypnotic medications for insomnia or anxiety.

199 tidepressant, antipsychotic, anxiolytic, and hypnotic medications in the 12 weeks before and after Se

200 inguish between these possibilities, we used hypnotic medications to control the amount of NREM sleep

201 hood of receiving antidepressant/antianxiety/hypnotic medications, and the number of psychotherapy se

202 ep regulation and for screening new types of hypnotic medications.

203 included in the prescribing information for hypnotic medications.

204 and/or HCRTR2 are considered to be potential hypnotic medications.

205 Evidence for benzodiazepine hypnotics, melatonin agonists, and antidepressants, and

206 reshold, 4 for genioglossus responsiveness), hypnotics minimally raised arousal threshold (mean diffe

207 al connectivity analysis indicated that this hypnotic modulation of pain responses was associated wit

208 ent treatment with antipsychotic, anxiolytic/hypnotic, mood stabilizer, and stimulant medications.

209 ntipsychotics, antidepressants, anxiolytics, hypnotics, mood stabilizers, and medications for attenti

210 tween DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatmen

211 is a place for the use of benzodiazepines/z-hypnotics on adult mental health wards, but they are oft

212 ns, involved in the use of benzodiazepines/z-hypnotics on adult mental health wards, were conducted a

213 acilitate deprescribing of benzodiazepines/z-hypnotics on adult mental health wards.

214 Objectives: To examine the effect of common hypnotics on arousal threshold, OSA severity, and geniog

215 r barrier to deprescribing benzodiazepines/z-hypnotics on these wards.

216 pidem, a widely prescribed nonbenzodiazepine hypnotic, on cell proliferation and survival in the dent

217 Use of benzodiazepines, nonbenzodiazepine hypnotics, opioid analgesics, and other PDI medications

218 chostimulants, antidepressants, anxiolytics, hypnotics or sedatives, or antipsychotics or prescriptio

219 ents beginning treatment with benzodiazepine hypnotics or z-drugs, we compared deaths during periods

220 eone (OR 3.70, 95% CI 2.30-5.95), and use of hypnotics (OR 2.28, 95% CI 1.20-4.30).

221 ercentage of patients with benzodiazepine, Z-hypnotic, or SSRI or SNRI prescriptions by sex was calcu

222 Prescription of a benzodiazepine, Z-hypnotic, or SSRI or SNRI.

223 Patients may use sedatives, hypnotics, or alcohol in an effort to interrupt this pro

224 tion (TV) and exposure to opioids, sedatives-hypnotics, or general anaesthetics in neonates (O-SH-GA)

225 for deprescribing (antipsychotics, sedative-hypnotics, or strong anticholinergics).

226 deaths have been reported from single-agent hypnotic overdoses.

227 iscontinuing benzodiazepine receptor agonist hypnotics (particularly in older adults) and administeri

228 Antidepressant, antipsychotic, and sedative-hypnotic prescriptions were negatively associated with p

229 pain, and demonstrate the possibility to use hypnotic procedures to modulate higher-level emotional a

230 t of the surgical patient for their sedative/hypnotic properties although the alpha2 adrenoceptor sub

231 data suggest that at least one aspect of the hypnotic properties of adenosine is mediated by a direct

232 ie the increased sensitivity to the sedative/hypnotic properties of ethanol but not the rewarding pro

233 ks and that such actions contribute to their hypnotic properties.

234 The unique, hypnotic pulsation behavior of certain soft corals of th

235 ff-label low-dose quetiapine for sedative or hypnotic purposes should be discouraged.

236 sed off-label at low doses for anxiolytic or hypnotic purposes, and its cardiovascular safety at thes

237 doses, commonly used off-label for sedative-hypnotic purposes, are also associated with increased ri

238 renatal exposure to benzodiazepines and/or z-hypnotics, regardless of timing of exposure and number o

239 equests to provide detailed case reports for hypnotic-related suicide deaths reported through its Adv

240 (n=79), structured attention (n=80), or self-hypnotic relaxation (n=82).

241 Structured attention and self-hypnotic relaxation proved beneficial during invasive me

242 In hypnotic responding, expectancies arising from imaginati

243 ha2A antisense ODNs significantly change the hypnotic response causing both an increase in latency to

244 f righting reflex following dexmedetomidine; hypnotic response had normalized 8 d after stopping the

245 addition, CIE rats showed remarkably reduced hypnotic response to a benzodiazepine and a steroid anes

246 eus of chronically cannulated rats and their hypnotic response to dexmedetomidine (an alpha2 agonist)

247 adrenoceptor subtype is responsible for the hypnotic response to dexmedetomidine in the locus coerul

248 lation and that the VLPO likely mediates the hypnotic response to high levels of opioid analgesics.

249 ta subunit to GABA pharmacology and sedative/hypnotic responses and behavior and provide insights int

250 onged hypotensive, bradycardic, and sedative-hypnotic responses to alpha(2)AR stimulation.

251 ilin on alpha(2)AR-evoked cardiovascular and hypnotic responses, previously demonstrated to be mediat

252 ions, including antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants, and psychostimula

253 tipsychotics: AOR, 4.74 [95% CI, 3.92-5.74]; hypnotics-sedatives: AOR, 3.01 [95% CI, 2.53-3.57]; and

254 tipsychotics: AOR, 6.20 [95% CI, 5.07-7.59]; hypnotics-sedatives: AOR, 4.45 [95% CI, 3.78-5.23]; anta

255 analgesics (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/sedatives (HR, 1.21; 95% CI, 1.07 to 1.37), an

256 analgesics (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/sedatives (HR, 1.24; 95% CI, 1.07 to 1.43), GI

257 rst-line guideline-recommended treatment, or hypnotics/sedatives improves heart- or brain-related out

258 coupled with a prescription for anxiolytics/hypnotics/sedatives, antidepressants, antipsychotics, or

259 etomidate had no effect on HCN1 channels and hypnotic sensitivity to etomidate was unaffected by HCN1

260 In addition, hypnotic sensitivity to two other intravenous anesthetic

261 rgeted medication classes (opioids, sedative-hypnotics, skeletal muscle relaxants, tricyclic antidepr

262 We outline how the hypnotic state can serve as a way to tap neurocognitive

263 bility/automaticity that characterize formal hypnotic states.

264 The second described a sedative-hypnotic, such as zolpidem, being used for insomnia by a

265 There is no association between hypnotics, such as zopiclone, and sleep outcomes, alertn

266 science has not fully exploited hypnosis and hypnotic suggestion as experimental tools.

267 We previously showed that a specific hypnotic suggestion reduces involuntary conflict and alt

268 is study was designed to determine whether a hypnotic suggestion to hinder lexical processing could m

269 and anxiety can be effectively alleviated by hypnotic suggestion, which modulates activity in brain r

270 Participants were stringently screened for hypnotic susceptibility with two standardized scales, an

271 For sedative-hypnotics, the phrase about side effects was 8.6-fold (9

272 ssant that was used clinically as a sedative-hypnotic, then became a notorious recreational drug in t

273 p randomized controlled trial of zolpidem-CR hypnotic therapy compared with placebo, in conjunction w

274 e of substance use disorder initiating study hypnotic therapy from January 2014 through September 201

275 The hypnotic THIP (Gaboxadol) induces SWA and at low, clinic

276 ) positive modulators commonly prescribed as hypnotics to treat insomnia and/or anxiety.

277 he effects of initiating benzodiazepine or z-hypnotic treatment in early, mid, and late pregnancy on

278 diabetes, hypertension, and beta-blocker or hypnotic treatments.

279 e impairment, while anxiolytic, sedative, or hypnotic use (HR, 0.88; 95% CI, 0.83-0.94) was associate

280 ; 95% CI, 5.39-6.77), especially sedative or hypnotic use disorders (HR, 32.24; 95% CI, 23.29-44.64).

281 sociated with the development of sedative or hypnotic use disorders up to 5 years (HR, 66.69; 95% CI,

282 ernal self-report of benzodiazepine and/or z-hypnotic use during pregnancy was grouped into early pre

283 we compared deaths during periods of current hypnotic use, without or with concurrent opioids, to tho

284 age, diagnosis status, gender, sedatives and hypnotics use, and hypertension.

285 r sleep was defined as >/=2 prescriptions of hypnotics using prospective data from the National Presc

286 pidem (Ambien), a short-acting GABAA agonist hypnotic, we show increased sleep spindle density and de

287 Hypnotics were hypothesized as an alternative OSA treatm

288 otics, z-drugs, or low-dose trazodone, study hypnotics were not associated with mortality.

289 n which neither antidepressants nor sedative/hypnotics were prescribed.

290 hdrawal events involving opioids or sedative-hypnotics were the main safety outcome.

291 avirus disease 2019 received higher doses of hypnotics, which was associated with prolonged coma and

292 ly in elderly patients taking benzodiazepine hypnotics, who comprise a large proportion of the depend

293 99% CI, 6.77-35.31); and 2 or more sedative-hypnotics, with anxiety disorders (OR, 2.13; 99% CI, 1.4

294 .3), is associated with less severe sedative-hypnotic withdrawal.

295 hypnotics and the related nonbenzodiazepine hypnotics (z-drugs) are among the most frequently prescr

296 ften treated with nonbenzodiazepine sedative hypnotics (Z-drugs).

297 Nonbenzodiazepine hypnotics ("Z-drugs") are prescribed for insomnia but mi

298 who initiated treatment with benzodiazepine hypnotics, z-drugs, or low-dose trazodone, study hypnoti

299 sure (CPAP) manipulations indicated that the hypnotic zolpidem increases the arousal threshold and ge

300 from pentobarbital as well as other sedative-hypnotics (zolpidem and ethanol) versus wild-type litter